不同剂量瑞舒伐他汀对急性冠脉综合征患者血清炎症因子和颈动脉斑块的影响(4)
[11] Kleemann R，Zadelaar S，Kooistra T. Cytokines and atherosclerosis：A comprehensive review of studies in mice[J]. Cardiovasc Res，2008，79(3)：360-376.
[12] Kotani T，Takeuchi T，Takai S，et al. Serum levels of matrix metalloproteinase(MMP) 9，a risk factor for acute coronary syndrome，are reduced independently of serim MMP-3 by anti-TNF-α antibody(infliximab) therapy in patients with rheumatoid arthritis[J]. J Pharmacol Sci，2012，120(1)：50-53.
[13] Schmidt R，Bültmann A，Ungerer M，et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells：Implications in acute myocardial infarction[J]. Circulation，2006，113(6)：834-841.
[14] Kanda T，Takahashi T. Interleukin-6 and cardiovascular diseases[J]. Jpn Heart J，2004，45(2)：183-193.
[15] Kim YR，Park JH，Lee HJ. The effect of doubling the statin dose on pro-inflammatory cytokine in patients with triple-vessel coronary artery disease[J]. Korean Circ J，2012，42(9)：595-599.
[16] Seo Y，Watanabe S，Ishizu T，et al. Echolucent carotid plaques as a feature in patients with acute coronary syndrome[J]. Circ J，2006，70(12)：1629-1634.
[17] Smith SC Jr，Greenland P，Grundy SM. AHA Conference Proceedings. Prevention conference V：Beyond secondary prevention：Identifying the high-risk patient for primary prevention：executive summary.American Heart Association[J].Circulation，2000，101(1)：111-116.
(收稿日期：2015-06-25), http://www.100md.com(董志华)
[12] Kotani T，Takeuchi T，Takai S，et al. Serum levels of matrix metalloproteinase(MMP) 9，a risk factor for acute coronary syndrome，are reduced independently of serim MMP-3 by anti-TNF-α antibody(infliximab) therapy in patients with rheumatoid arthritis[J]. J Pharmacol Sci，2012，120(1)：50-53.
[13] Schmidt R，Bültmann A，Ungerer M，et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells：Implications in acute myocardial infarction[J]. Circulation，2006，113(6)：834-841.
[14] Kanda T，Takahashi T. Interleukin-6 and cardiovascular diseases[J]. Jpn Heart J，2004，45(2)：183-193.
[15] Kim YR，Park JH，Lee HJ. The effect of doubling the statin dose on pro-inflammatory cytokine in patients with triple-vessel coronary artery disease[J]. Korean Circ J，2012，42(9)：595-599.
[16] Seo Y，Watanabe S，Ishizu T，et al. Echolucent carotid plaques as a feature in patients with acute coronary syndrome[J]. Circ J，2006，70(12)：1629-1634.
[17] Smith SC Jr，Greenland P，Grundy SM. AHA Conference Proceedings. Prevention conference V：Beyond secondary prevention：Identifying the high-risk patient for primary prevention：executive summary.American Heart Association[J].Circulation，2000，101(1)：111-116.
(收稿日期：2015-06-25), http://www.100md.com(董志华)